BETHESDA, Md.--(BUSINESS WIRE)--Sucampo Pharmaceuticals, Inc. (NASDAQ: SCMP) today reported its financial results for the third quarter and nine months ended September 30, 2007.
“I am very pleased with the accomplishment of so many operational and financial highlights in the third quarter,” said Ryuji Ueno, M.D., Ph.D., Ph.D., the Company’s founder, chairman and chief executive officer. “We were able to meet our goals of successfully completing our initial public offering (IPO), internalizing our contract sales force, and enrolling our first patients in two clinical trials – Phase III pivotal studies of lubiprostone for the treatment of opioid-induced bowel dysfunction (OBD) and a multi-center Phase II dose-finding trial of cobiprostone (SPI-8811), for the prevention of ulcers and other gastrointestinal injuries in arthritis patients treated with nonsteroidal anti-inflammatory drugs (NSAIDs). These studies underscore our drug development and commercialization strategy of targeting large and underserved markets, with an emphasis on diseases associated with an aging population.”
